Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines

Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular pharmaceutics 2016-03, Vol.13 (3), p.720-728
Hauptverfasser: Hill, Tanner K, Davis, Amanda L, Wheeler, Frances B, Kelkar, Sneha S, Freund, Erica C, Lowther, W. Todd, Kridel, Steven J, Mohs, Aaron M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 728
container_issue 3
container_start_page 720
container_title Molecular pharmaceutics
container_volume 13
creator Hill, Tanner K
Davis, Amanda L
Wheeler, Frances B
Kelkar, Sneha S
Freund, Erica C
Lowther, W. Todd
Kridel, Steven J
Mohs, Aaron M
description Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.
doi_str_mv 10.1021/acs.molpharmaceut.5b00447
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4783219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1771450284</sourcerecordid><originalsourceid>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</originalsourceid><addsrcrecordid>eNqNkd1u0zAYhiMEYmNwC8iccbAU23Hi5ARpKoxNqqgEPbe-OM7qyT_BdjZ6C1w1Li0VO-PIlvy8j_35LYp3BC8IpuQDyLiw3kxbCBakmtOi7jFmjD8rzknNqrKtOvr8tG_ZWfEqxnuMKatp9bI4o01LGWH0vPj1ST0o4yerXEJ-RIC-KzOWVzEq2xs1oK_g_AQhaWkUuvbBzgaS9m4Pr4PRMUG6_EOV62-rS_So0xbdOhkUxBxf7pJP_qeWOu0Q3IF2MaGb2YJDm9n6gJbKGLTSTsXXxYsRTFRvjutFsbn-vFnelKv1l9vl1aoE1nSphH6ktG4w51XF-542wDFwMjJGRlwNcmhqSTjuJK5IO6ix7wZZE8LHumvZ0FYXxceDdpp7qwaZBw9gxBS0hbATHrR4euL0Vtz5B8F4W1HSZcH7oyD4H7OKSVgdZR4DnPJzFIRzwmpMW5bR7oDK4GMMajxdQ7DYVylyleJJleJYZc6-_fedp-Tf7jJQH4C9497PweVf-w_xb4hdtcA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771450284</pqid></control><display><type>article</type><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><source>MEDLINE</source><source>ACS Publications</source><creator>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</creator><creatorcontrib>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</creatorcontrib><description>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (&gt;85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/acs.molpharmaceut.5b00447</identifier><identifier>PMID: 26824142</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Apoptosis - drug effects ; Breast Neoplasms - drug therapy ; Breast Neoplasms - enzymology ; Breast Neoplasms - pathology ; Cell Proliferation - drug effects ; Drug Compounding ; Enzyme Inhibitors - administration &amp; dosage ; Enzyme Inhibitors - pharmacology ; Fatty Acid Synthases - antagonists &amp; inhibitors ; Fatty Acid Synthesis Inhibitors - administration &amp; dosage ; Fatty Acid Synthesis Inhibitors - pharmacology ; Female ; Humans ; Lactones - administration &amp; dosage ; Lactones - pharmacology ; Male ; Mitochondria - drug effects ; Mitochondria - enzymology ; Nanoparticles - administration &amp; dosage ; Nanoparticles - chemistry ; Orlistat ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - enzymology ; Prostatic Neoplasms - pathology ; Tumor Cells, Cultured</subject><ispartof>Molecular pharmaceutics, 2016-03, Vol.13 (3), p.720-728</ispartof><rights>Copyright © 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</citedby><cites>FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00447$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5b00447$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,776,780,881,2751,27055,27903,27904,56716,56766</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26824142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hill, Tanner K</creatorcontrib><creatorcontrib>Davis, Amanda L</creatorcontrib><creatorcontrib>Wheeler, Frances B</creatorcontrib><creatorcontrib>Kelkar, Sneha S</creatorcontrib><creatorcontrib>Freund, Erica C</creatorcontrib><creatorcontrib>Lowther, W. Todd</creatorcontrib><creatorcontrib>Kridel, Steven J</creatorcontrib><creatorcontrib>Mohs, Aaron M</creatorcontrib><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (&gt;85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</description><subject>Apoptosis - drug effects</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - enzymology</subject><subject>Breast Neoplasms - pathology</subject><subject>Cell Proliferation - drug effects</subject><subject>Drug Compounding</subject><subject>Enzyme Inhibitors - administration &amp; dosage</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fatty Acid Synthases - antagonists &amp; inhibitors</subject><subject>Fatty Acid Synthesis Inhibitors - administration &amp; dosage</subject><subject>Fatty Acid Synthesis Inhibitors - pharmacology</subject><subject>Female</subject><subject>Humans</subject><subject>Lactones - administration &amp; dosage</subject><subject>Lactones - pharmacology</subject><subject>Male</subject><subject>Mitochondria - drug effects</subject><subject>Mitochondria - enzymology</subject><subject>Nanoparticles - administration &amp; dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Orlistat</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - enzymology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Tumor Cells, Cultured</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd1u0zAYhiMEYmNwC8iccbAU23Hi5ARpKoxNqqgEPbe-OM7qyT_BdjZ6C1w1Li0VO-PIlvy8j_35LYp3BC8IpuQDyLiw3kxbCBakmtOi7jFmjD8rzknNqrKtOvr8tG_ZWfEqxnuMKatp9bI4o01LGWH0vPj1ST0o4yerXEJ-RIC-KzOWVzEq2xs1oK_g_AQhaWkUuvbBzgaS9m4Pr4PRMUG6_EOV62-rS_So0xbdOhkUxBxf7pJP_qeWOu0Q3IF2MaGb2YJDm9n6gJbKGLTSTsXXxYsRTFRvjutFsbn-vFnelKv1l9vl1aoE1nSphH6ktG4w51XF-542wDFwMjJGRlwNcmhqSTjuJK5IO6ix7wZZE8LHumvZ0FYXxceDdpp7qwaZBw9gxBS0hbATHrR4euL0Vtz5B8F4W1HSZcH7oyD4H7OKSVgdZR4DnPJzFIRzwmpMW5bR7oDK4GMMajxdQ7DYVylyleJJleJYZc6-_fedp-Tf7jJQH4C9497PweVf-w_xb4hdtcA</recordid><startdate>20160307</startdate><enddate>20160307</enddate><creator>Hill, Tanner K</creator><creator>Davis, Amanda L</creator><creator>Wheeler, Frances B</creator><creator>Kelkar, Sneha S</creator><creator>Freund, Erica C</creator><creator>Lowther, W. Todd</creator><creator>Kridel, Steven J</creator><creator>Mohs, Aaron M</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160307</creationdate><title>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</title><author>Hill, Tanner K ; Davis, Amanda L ; Wheeler, Frances B ; Kelkar, Sneha S ; Freund, Erica C ; Lowther, W. Todd ; Kridel, Steven J ; Mohs, Aaron M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a469t-abf2256077337bb26a70a71f441f03dcd65c1709c0318defb9dc5117f5984d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis - drug effects</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - enzymology</topic><topic>Breast Neoplasms - pathology</topic><topic>Cell Proliferation - drug effects</topic><topic>Drug Compounding</topic><topic>Enzyme Inhibitors - administration &amp; dosage</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fatty Acid Synthases - antagonists &amp; inhibitors</topic><topic>Fatty Acid Synthesis Inhibitors - administration &amp; dosage</topic><topic>Fatty Acid Synthesis Inhibitors - pharmacology</topic><topic>Female</topic><topic>Humans</topic><topic>Lactones - administration &amp; dosage</topic><topic>Lactones - pharmacology</topic><topic>Male</topic><topic>Mitochondria - drug effects</topic><topic>Mitochondria - enzymology</topic><topic>Nanoparticles - administration &amp; dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Orlistat</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - enzymology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hill, Tanner K</creatorcontrib><creatorcontrib>Davis, Amanda L</creatorcontrib><creatorcontrib>Wheeler, Frances B</creatorcontrib><creatorcontrib>Kelkar, Sneha S</creatorcontrib><creatorcontrib>Freund, Erica C</creatorcontrib><creatorcontrib>Lowther, W. Todd</creatorcontrib><creatorcontrib>Kridel, Steven J</creatorcontrib><creatorcontrib>Mohs, Aaron M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hill, Tanner K</au><au>Davis, Amanda L</au><au>Wheeler, Frances B</au><au>Kelkar, Sneha S</au><au>Freund, Erica C</au><au>Lowther, W. Todd</au><au>Kridel, Steven J</au><au>Mohs, Aaron M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2016-03-07</date><risdate>2016</risdate><volume>13</volume><issue>3</issue><spage>720</spage><epage>728</epage><pages>720-728</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of 14C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (&gt;85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>26824142</pmid><doi>10.1021/acs.molpharmaceut.5b00447</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2016-03, Vol.13 (3), p.720-728
issn 1543-8384
1543-8392
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4783219
source MEDLINE; ACS Publications
subjects Apoptosis - drug effects
Breast Neoplasms - drug therapy
Breast Neoplasms - enzymology
Breast Neoplasms - pathology
Cell Proliferation - drug effects
Drug Compounding
Enzyme Inhibitors - administration & dosage
Enzyme Inhibitors - pharmacology
Fatty Acid Synthases - antagonists & inhibitors
Fatty Acid Synthesis Inhibitors - administration & dosage
Fatty Acid Synthesis Inhibitors - pharmacology
Female
Humans
Lactones - administration & dosage
Lactones - pharmacology
Male
Mitochondria - drug effects
Mitochondria - enzymology
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Orlistat
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - enzymology
Prostatic Neoplasms - pathology
Tumor Cells, Cultured
title Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T20%3A13%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Self-Assembled%20Nanoparticle%20Formulation%20of%20Orlistat,%20Nano-ORL,%20with%20Increased%20Cytotoxicity%20against%20Human%20Tumor%20Cell%20Lines&rft.jtitle=Molecular%20pharmaceutics&rft.au=Hill,%20Tanner%20K&rft.date=2016-03-07&rft.volume=13&rft.issue=3&rft.spage=720&rft.epage=728&rft.pages=720-728&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/acs.molpharmaceut.5b00447&rft_dat=%3Cproquest_pubme%3E1771450284%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771450284&rft_id=info:pmid/26824142&rfr_iscdi=true